Pasar al contenido principal

DESCIFRANDO EL PAPEL DE LA NADPH OXIDASA NOX4 EN EL CARCINOMA HEPATOCELULAR: RELEVANCIA EN CELULAS TUMORALES Y ESTROMA Y RELACION CON LA VIA DEL TGF-BETA

PID2021-122551OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO INSTITUT D INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The NADPH oxidase NOX4 regulates redox and metabolic homeostasis preventing HCC progression

  • Peñuelas-Haro, Irene
  • Espinosa-Sotelo, Rut
  • Crosas-Molist, Eva
  • Herranz-Itúrbide, Macarena
  • Caballero-Díaz, Daniel
  • Alay, Ania
  • Solé, Xavier
  • Ramos, Emilio
  • Serrano, Teresa
  • Martínez-Chantar, María Luz
  • Knaus, Ulla G.
  • Cuezva, José M.
  • Zorzano, Antonio
  • Bertran, Esther
  • Fabregat, Isabel
Background and aims: The NADPH oxidase NOX4 plays a tumor-suppressor function in HCC. Silencing NOX4 confers higher proliferative and migratory capacity to HCC cells and increases their in vivo tumorigenic potential in xenografts in mice. NOX4 gene deletions are frequent in HCC, correlating with higher tumor grade and worse recurrence-free and overall survival rates. However, despite the accumulating evidence of a protective regulatory role in HCC, the cellular processes governed by NOX4 are not yet understood. Accordingly, the aim of this work was to better understand the molecular mechanisms regulated by NOX4 in HCC in order to explain its tumor-suppressor action. Approach and results: Experimental models: cell-based loss or gain of NOX4 function experiments, in vivo hepatocarcinogenesis induced by diethylnitrosamine in Nox4-deficient mice, and analyses in human HCC samples. Methods include cellular and molecular biology analyses, proteomics, transcriptomics, and metabolomics, as well as histological and immunohistochemical analyses in tissues. Results identified MYC as being negatively regulated by NOX4. MYC mediated mitochondrial dynamics and a transcriptional program leading to increased oxidative metabolism, enhanced use of both glucose and fatty acids, and an overall higher energetic capacity and ATP level. NOX4 deletion induced a redox imbalance that augmented nuclear factor erythroid 2-related factor 2 (Nrf2) activity and was responsible for MYC up-regulation. Conclusions: Loss of NOX4 in HCC tumor cells induces metabolic reprogramming in a Nrf2/MYC-dependent manner to promote HCC progressio, Supported by Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación, Spain (co‐funded by European Regional Development Fund ERDF, a way to build Europe) (SAF2015‐64149‐R, RTI2018‐094079‐B‐100, PID2021‐122551OB‐I00, PID2019‐106209RB‐I00, PID2019‐108674RB‐100, and RED2018‐102576‐T); FPI fellowships (BES‐2016‐077564 and PRE2019‐089144); the Generalitat de Catalunya (2017SGR1015); Science Foundation Ireland (16/IA/4501); CIBER, National Biomedical Research Institute, which is funded by the Instituto de Salud Carlos III, Spain; CERCA Programme/Generalitat de Catalunya; and an ICREA “Academia” Award (Generalitat de Catalunya)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Iron chelation as a new therapeutic approach to prevent senescence and liver fibrosis progression

  • Josep Amengual, Josep
  • Alay, Ania
  • Vaquero, Javier
  • Gonzalez-Sanchez, Ester
  • Bertran, Esther
  • Sánchez, Aranzazu
  • Herrera, Blanca
  • Meyer, Kathleen
  • Maus, Mate
  • Serrano, Manuel
  • Martínez-Chantar, María Luz
  • Fabregat, Isabel
Iron overload and cellular senescence have been implicated in liver fibrosis, but their possible mechanistic connection has not been explored. To address this, we have delved into the role of iron and senescence in an experimental model of chronic liver injury, analyzing whether an iron chelator would prevent liver fibrosis by decreasing hepatocyte senescence. The model of carbon tetrachloride (CCl4) in mice was used as an experimental model of liver fibrosis. Results demonstrated that during the progression of liver fibrosis, accumulation of iron occurs, concomitant with the appearance of fibrotic areas and cells undergoing senescence. Isolated parenchymal hepatocytes from CCl4-treated mice present a gene transcriptomic signature compatible with iron accumulation and senescence, which correlates with induction of Reactive Oxygen Species (ROS)-related genes, activation of the Transforming Growth Factor-beta (TGF-β) pathway and inhibition of oxidative metabolism. Analysis of the iron-related gene signature in a published single-cell RNA-seq dataset from CCl4-treated livers showed iron accumulation correlating with senescence in other non-parenchymal liver cells. Treatment with deferiprone, an iron chelator, attenuated iron accumulation, fibrosis and senescence, concomitant with relevant changes in the senescent-associated secretome (SASP), which switched toward a more anti-inflammatory profile of cytokines. In vitro experiments in human hepatocyte HH4 cells demonstrated that iron accumulates in response to a senescence-inducing reagent, doxorubicin, being deferiprone able to prevent senescence and SASP, attenuating growth arrest and cell death. However, deferiprone did not significantly affect senescence induced by two different agents (doxorubicin and deoxycholic acid) or activation markers in human hepatic stellate LX-2 cells. Transcriptomic data from patients with different etiologies demonstrated the relevance of iron accumulation in the progression of liver chronic damage and fibrosis, correlating with a SASP-related gene signature and pivotal hallmarks of fibrotic changes. Altogether, our study establishes iron accumulation as a clinically exploitable driver to attenuate pathological senescence in hepatocytes., This study was funded by (1) Ministerio de Ciencia e Innovación (MICINN), Spain, which is part of the Agencia Estatal de Investigación (AEI), through: (a) the Retos Colaboración grant #RTC2019-007125-1 and (b) the Retos Investigación grant #PID2021-122551OB-100 funded by MCIN/AEI/10.13039/501100011033/FEDER, UE; (2) Fundación Ramon Areces, grant #CIVP20A6593. The CIBEREHD is funded by the Instituto de Salud Carlos III, Spain. We thank the CERCA Programme/Generalitat de Catalunya for institutional support., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The hepatocyte epidermal growth factor receptor (EGFR) pathway regulates the cellular interactome within the liver fibrotic niche

  • Gonzalez-Sanchez, Ester
  • Vaquero, Javier
  • Caballero-Díaz, Daniel
  • Grzelak, Jan
  • Fusté, Noel P.
  • Bertran, Esther
  • Amengual, Josep
  • Garcia-Saez, Juan
  • Martín-Mur, Beatriz
  • Gut, Marta
  • Esteve-Codina, Anna
  • Alay, Ania
  • Coulouarn, Cédric
  • Calero-Pérez, Silvia
  • Valdecantos, Pilar
  • Valverde, Ángela M.
  • Sánchez, Aranzazu
  • Herrera, Blanca
  • Fabregat, Isabel
Liver fibrosis is the consequence of chronic liver injury in the presence of an inflammatory component. Although the main executors of this activation are known, the mechanisms that lead to the inflammatory process that mediates the production of pro-fibrotic factors are not well characterized. Epidermal growth factor receptor (EGFR) signaling in hepatocytes is essential for the regenerative processes of the liver; however, its potential role in regulating the fibrotic niche is not yet clear. Our group generated a mouse model that expresses an inactive truncated form of the EGFR specifically in hepatocytes (ΔEGFR mice). Here, we have analyzed the response of WT and ΔEGFR mice to chronic treatment with carbon tetrachloride (CCl4), which induces a pro-inflammatory and fibrotic process in the liver. The results indicated that the hallmarks of liver fibrosis were attenuated in CCl4-treated ΔEGFR mice when compared with CCl4-treated WT mice, coinciding with a faster resolution of the fibrotic process and ameliorated damage. The absence of EGFR activity in hepatocytes induced changes in the pattern of immune cells in the liver, with a notable increase in the population of M2 macrophages, more related to fibrosis resolution, as well as in the population of lymphocytes related to eradication of the damage. Transcriptome analysis of hepatocytes, and secretome studies of extracellular media from in vitro experiments, allowed us to elucidate the specific molecular mechanisms regulated by EGFR that mediate hepatocyte production of both pro-fibrotic and pro-inflammatory mediators; these have consequences for the deposition of extracellular matrix proteins, as well as for the immune microenvironment. Overall, our study uncovered novel mechanistic insights regarding EGFR kinase-dependent actions in hepatocytes that reveal its key role in chronic liver damage., This work was supported by (i) Fundacion Ramon Areces 20th National Competition for Scientific and Technical Research in Life and Matter Science 2020, grant # CIVP20A6593, to IF; (ii) Ministerio de Ciencia e Innovación (MICINN), Spain, which is part of the Agencia Estatal de Investigación (AEI), through (a) the Retos Investigación grants, numbers: RTI2018-094079-B-100 (co-funded by European Regional Development Fund, ERDF, a way to build Europe) to IF; PID2021-122551OB-100 funded by MCIN/AEI/10.13039/501100011033/FEDER, UE to IF; RTI2018-099098-B-100 funded by MCIN/AEI/10.13039/501100011033/FEDER, UE to AS/BH; PID-2021-122766OB-100 funded by MCIN/AEI/10.13039/501100011033 to AMV; and (b) the Retos Colaboración grant number RTC2019-007125-1 to IF. JV was funded by MICINN/AEI, through the Retos Investigación grant number PID2019-108651RJ-I00/DOI 10.13039/501100011033 and ‘Ramon y Cajal’ program RYC2021-034121-I. The CIBEREHD, National Biomedical Research Institute on Liver and Gastrointestinal Diseases, is funded by the Instituto de Salud Carlos III, Spain. We thank CERCA Programme/Generalitat de Catalunya for institutional support., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Sequential activation of transcription factors promotes liver regeneration through specific and developmental enhancers

  • Llorens-Giralt, Palmira
  • Ruiz-Romero, Marina
  • Nurtdinov, Ramil
  • Herranz-Itúrbide, Macarena
  • Vicent, Guillermo P.
  • Serras, Florenci
  • Fabregat, Isabel
  • Corominas, Montserrat
The mammalian liver exhibits remarkable regenerative capabilities after injury or resection. Central to this process is the precise modulation of gene expression, driven by changes in chromatin structure and the temporal activation of distal regulatory elements. In this study, we integrated chromatin accessibility and transcriptomic data after partial hepatectomy in mice. We show that the expression of crucial regeneration genes is orchestrated by a diverse array of cis-regulatory elements, including regeneration-specific enhancers and enhancers repurposed from various developmental stages. These enhancers collaborate to activate the transcriptional programs required for hepatocyte priming and proliferation, with their activity initially regulated by the activator protein-1 (AP-1) complex and ATF3, and subsequently by nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) during proliferation. Our results also indicate that hepatic regeneration involves the repression of enhancers regulating liver-specific metabolic functions, particularly those involved in lipid metabolism. This study provides a genome-wide atlas of enhancer-gene interactions, offering new insights into the regulatory mechanisms underlying liver regeneration., This project was funded by PID2021-123300NB-100 from MCIN/AEI/10.13039/501100011033/FEDER, UE to F.S and M.C.; 2021SGR00293 from the Agency for the Management of University and Research Grants (Generalitat de Catalunya) to M.C.; PID2021-122551OB-100 from MCIN/AEI/10.13039/501100011033/FEDER, UE to I.F.; and FPU20/01473 from the Spanish Ministerio de Universidades to P.L.G. We thank R. Guigó for financial support to M.R.R. and R.N. through grant PID2021-128956NB-I00 funded by MCIN/AEI/10.13039/501100011033/FEDER, UE. M.R.R. and R.N. acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S and MCIN/AEI/10.13039/501100011033) and the Generalitat de Catalunya through the CERCA program., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2020-001049-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

New Experimental Mouse Models to Evaluate the Role of Transforming Growth Factor-Beta in Liver Tumorigenesis

  • Cantos-Cortes, Ana
  • Amengual, Josep
  • Espinosa-Sotelo, Rut
  • Bertran, Esther
  • Vaquero, Javier
  • Ruiz de Galarreta, Marina
  • Molina-Sánchez, Pedro
  • Serrano, Teresa
  • Ramos, Emilio
  • Calvo, Mariona
  • Scialpi, Rosanna
  • Dituri, Francesco
  • Giannelli, Gianluigi
  • Lujambio, Amaia
  • Gonzalez-Sanchez, Ester
  • Fabregat, Isabel
[Background and Aims] Hepatocellular carcinoma (HCC) has a poor prognosis and limited treatment options. TGF-β is a promising therapeutic target, but its dual role, as both a tumour suppressor and promoter, complicates its clinical application. While its effects on tumour cells are increasingly understood, its impact on the tumour stroma remains unclear. This study developed novel in vitro and in vivo mouse models to investigate the role of TGF-β in tumour–stroma interactions under immunocompetent conditions, aiming to evaluate its therapeutic potential in liver cancer., [Methods] Mouse liver tumour cell lines were established by hydrodynamic tail vein injection of two different combinations of transposon vector constructions: MYC-LucOS;CTNNB1;SB13 (AL1099 cells) and MYC-Luc;CTNNB1;SB13 (AL1184 cells) to be used in in vitro and in vivo studies., [Results] These cell lines exhibited contrasting phenotypes and responses to TGF-β. We selected AL1099 cells, which displayed an epithelial phenotype and responded to TGF-β with growth inhibition, apoptosis, and induction of Epithelial-Mesenchymal Transition (EMT), and AL1184 cells, which exhibited a mesenchymal-like phenotype and showed enhanced proliferation in response to TGF-β. Both cell lines demonstrated robust growth in 2D and 3D cultures and were co-cultured with RAW 264.7 macrophages, GRX hepatic stellate cells, or both, to explore tumour-stroma interactions. Importantly, AL1099 and AL1184 cells were able to grow in vivo, forming tumours in syngeneic orthotopic models suitable for pharmacological studies., [Conclusions] Together, these findings highlight the value of these models for advancing therapeutic strategies targeting TGF-β, either alone or in combination with immunotherapy, in liver cancer., This work was supported by Fundación Científica Asociación Española Contra el Cáncer, PRYGN211279FABR; Ministerio de Ciencia e Innovación, PID2021-122551OB-100, RYC2021-034121-I; Direcció General de Recerca, Generalitat de Catalunya, #2021 SGR 00029; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, CB17/04/00017. Ester Gonzalez-Sanchez and Isabel Fabregat are co-senior authors., Peer reviewed